Physician profile
Daniel J Dewinter
NPI 1790754968
$3,504.59
in general payments reported to CMS, 2019-2025
13 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $121 · 2021: $603 · 2022: $775 · 2023: $495 · 2024: $512 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225 · Entertainment: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.68 |
| Entertainment | $155.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,782.90 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Coopervision INC. | $332.64 | 2019-2023 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $202.72 | 2019-2021 | |
| Allergan, INC. | $198.89 | 2021-2022 | |
| Optos, INC. | $166.37 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $140.85 | 2019 | |
| Sight Sciences, INC. | $139.99 | 2022 | |
| Horizon Therapeutics Plc | $121.83 | 2022 | |
| Glaukos Corporation | $115.30 | 2025 | Idosetr |
| Astellas Pharma US INC | $87.98 | 2024 | Izervay |
| The Walman Optical Company | $79.00 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $71.42 | 2025 | |
| Abbvie INC. | $64.70 | 2023 | Xen Glaucoma Treatment System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dewinter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.